These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 3326605)

  • 21. Induction of petite formation in Saccharomyces cerevisiae by experimental antitumour agents. Structure--activity relationships for 9-anilinoacridines.
    Ferguson LR; Baguley BC
    Mutat Res; 1981 Dec; 90(4):411-23. PubMed ID: 7038462
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Potential antitumor agents. 41. Analogues of amsacrine with electron-donor substituents in the anilino ring.
    Atwell GJ; Rewcastle GW; Denny WA; Cain BF; Baguley BC
    J Med Chem; 1984 Mar; 27(3):367-72. PubMed ID: 6546591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Potential antitumor agents. 47. 3'-Methylamino analogues of amsacrine with in vivo solid tumor activity.
    Atwell GJ; Baguley BC; Finlay GJ; Rewcastle GW; Denny WA
    J Med Chem; 1986 Sep; 29(9):1769-76. PubMed ID: 3755758
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Crosslinking of cellular DNA by nitracrine and furocoumarin derivatives.
    Studzian K; Tołwińska-Stańczyk Z; Wilmańska D; Palumbo M; Gniazdowski M
    Neoplasma; 1999; 46(1):50-3. PubMed ID: 10355534
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antitumor activity of patulin and structural analogs.
    Seigle-Murandi F; Steiman R; Krivobok S; Beriel H; Benoit-Guyod JL
    Pharmazie; 1992 Apr; 47(4):288-91. PubMed ID: 1518888
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Nitracrine N-oxides: effects of variations in the nature of the side chain N-oxide on hypoxia-selective cytotoxicity.
    Lee HH; Wilson WR; Denny WA
    Anticancer Drug Des; 1999 Dec; 14(6):487-97. PubMed ID: 10834270
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Potential antitumor agents. 40. Orally active 4,5-disubstituted derivatives of amsacrine.
    Denny WA; Atwell GJ; Baguley BC
    J Med Chem; 1984 Mar; 27(3):363-7. PubMed ID: 6546590
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide.
    Baguley BC; Denny WA; Atwell GJ; Finlay GJ; Rewcastle GW; Twigden SJ; Wilson WR
    Cancer Res; 1984 Aug; 44(8):3245-51. PubMed ID: 6547635
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential antitumor agents. 35. Quantitative relationships between antitumor (L1210) potency and DNA binding for 4'-(9-acridinylamino)methanesulfon-m-anisidide analogues.
    Baguley BC; Denny WA; Atwell GJ; Cain BF
    J Med Chem; 1981 May; 24(5):520-5. PubMed ID: 6894620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis and antitumor activity of pyrido-amsacrine analogues and related compounds.
    Llama E; Del Campo C; Capo M; Anadon M
    J Pharm Sci; 1993 Mar; 82(3):262-5. PubMed ID: 8450419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Study on the toxicity and antitumor activity of adriamycin-DNA and amsacrine-DNA complexes in mice].
    Zhang XG; Wu DZ
    Yao Xue Xue Bao; 1992; 27(11):801-5. PubMed ID: 1300022
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Lethal activity and kinetic response of cultured human cells to 4'-(9-acridinylamino)methanesulfon-m-anisidine.
    Drewinko B; Yang LY; Barlogie B
    Cancer Res; 1982 Jan; 42(1):107-11. PubMed ID: 6895609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Synthesis, antitumor activity, and cardiac toxicity of new 4-demethoxyanthracyclines.
    Penco S; Casazza AM; Franchi G; Barbieri B; Bellini O; Podestà A; Savi G; Pratesi G; Geroni C; Di Marco A; Arcamone F
    Cancer Treat Rep; 1983; 67(7-8):665-73. PubMed ID: 6575865
    [TBL] [Abstract][Full Text] [Related]  

  • 34. 32P-post-labeling analysis of DNA adduct formation by antitumor drug nitracrine (Ledakrin) and other nitroacridines in different biological systems.
    Bartoszek A; Konopa J
    Biochem Pharmacol; 1989 Apr; 38(8):1301-12. PubMed ID: 2706021
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutagenic activity of some 9-aminoalkyl acridine derivatives on S. typhimurium.
    Kalinowska E; Chorazy M
    Mutat Res; 1980 May; 78(1):7-15. PubMed ID: 6991931
    [TBL] [Abstract][Full Text] [Related]  

  • 36. (R,R)-2,2'-[1,2-ethanediylbis[imino(1-methyl-2,1-ethanediyl)]]- bis[5-nitro-1H-benz[de]isoquinoline-1,3-(2H)-dione] dimethanesulfonate (DMP 840), a novel bis-naphthalimide with potent nonselective tumoricidal activity in vitro.
    Kirshenbaum MR; Chen SF; Behrens CH; Papp LM; Stafford MM; Sun JH; Behrens DL; Fredericks JR; Polkus ST; Sipple P
    Cancer Res; 1994 Apr; 54(8):2199-206. PubMed ID: 8174127
    [TBL] [Abstract][Full Text] [Related]  

  • 37. DNA damage in HeLa s3 cells by an antitumor drug Ledakrin and other antitumor 1-nitro-9-aminoacridines.
    Woynarowski JM; Bartoszek A; Konopa J
    Chem Biol Interact; 1984 May; 49(3):311-28. PubMed ID: 6722943
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacological studies on new oncostatic acridine derivatives. II. Chronic action.
    Błaszczyk B; Giełdanowski J; Patkowski J; Kowalczyk-Bronisz SH
    Arch Immunol Ther Exp (Warsz); 1979; 27(6):765-76. PubMed ID: 549531
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Differential growth inhibition of cultured mammalian cells: comparison of clinical antitumour agents and amsacrine derivatives.
    Wilson WR; Tapp SM; Baguley BC
    Eur J Cancer Clin Oncol; 1984 Mar; 20(3):383-9. PubMed ID: 6546720
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antitumour activity of substituted 9-anilinoacridines--comparison of in vivo and in vitro testing systems.
    Baguley BC; Nash R
    Eur J Cancer (1965); 1981 Jun; 17(6):671-9. PubMed ID: 6895501
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.